These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36048970)

  • 1. Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B.
    Liem KS; Chi H; Fung S; Wong DK; Yim C; Noureldin S; Chen J; de Man RA; Sarowar A; Feld JJ; Hansen BE; Hou J; Peng J; Janssen HLA
    J Viral Hepat; 2022 Nov; 29(11):986-993. PubMed ID: 36048970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
    Wong D; Littlejohn M; Edwards R; Jackson K; Revill P; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti-Ferret M; Janssen H; Gane E; Locarnini S; Thompson A
    Liver Int; 2018 Oct; 38(10):1760-1769. PubMed ID: 29427368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flares during long-term entecavir therapy in chronic hepatitis B.
    Chi H; Arends P; Reijnders JG; Carey I; Brown A; Fasano M; Mutimer D; Deterding K; Oo YH; Petersen J; van Bommel F; de Knegt RJ; Santantonio TA; Berg T; Welzel TM; Wedemeyer H; Buti M; Pradat P; Zoulim F; Hansen BE; Janssen HL;
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1882-1887. PubMed ID: 27008918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
    Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
    Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
    Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
    Cao J; Chi H; Yu T; Li Z; Hansen BE; Zhang X; Zhong C; Sun J; Hou J; Janssen HLA; Peng J
    J Infect Dis; 2017 Feb; 215(4):581-589. PubMed ID: 28329347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.
    Choi HSJ; Sonneveld MJ; Farag MS; Brouwer WP; Brakenhoff SM; Hirode G; Gehring AJ; de Man RA; Hansen BE; Janssen HLA
    J Viral Hepat; 2021 Dec; 28(12):1729-1737. PubMed ID: 34514678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.
    Hall SAL; Burns GS; Anagnostou D; Vogrin S; Sundararajan V; Ratnam D; Levy MT; Lubel JS; Nicoll AJ; Strasser SI; Sievert W; Desmond PV; Ngu MC; Angus P; Sinclair M; Meredith C; Matthews G; Revill PA; Jackson K; Littlejohn M; Bowden DS; Locarnini SA; Visvanathan K; Thompson AJ
    Aliment Pharmacol Ther; 2022 Jul; 56(2):310-320. PubMed ID: 35521992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues.
    Manolakopoulos S; Kranidioti H; Kourikou A; Deutsch MM; Triantos C; Tsolias C; Manesis EK; Mathou N; Alexopoulou A; Hadziyannis E; Papatheodoridis G
    Liver Int; 2021 Jan; 41(1):48-57. PubMed ID: 33373114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of Long-Term Nucleotide Analog Therapy in Chronic Hepatitis B: Outcomes From the Withdrawal Phase of the HBRN Immune Active Treatment Trial.
    Feld JJ; Wahed AS; Fried M; Ghany MG; Di Bisceglie AM; Perrillo RP; Khalili M; Yang X; Belle SH; Janssen HLA; Terrault N; Lok AS;
    Am J Gastroenterol; 2023 Jul; 118(7):1226-1236. PubMed ID: 36728214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients.
    Liu YC; Jeng WJ; Peng CW; Chien RN; Liaw YF
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1533-1541.e11. PubMed ID: 36038130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.
    Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH
    Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained response and HBsAg loss after nucleo(s)tide analogue discontinuation in chronic hepatitis B patients: the prospective SNAP study.
    Brakenhoff SM; Claassen M; Honkoop P; de Knegt RJ; van der Eijk AA; Boonstra A; de Man RA; Sonneveld MJ
    Clin Res Hepatol Gastroenterol; 2024 Feb; 48(2):102257. PubMed ID: 38065523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare.
    Jeng WJ; Chen YC; Chang ML; Liaw YF
    J Antimicrob Chemother; 2016 Jun; 71(6):1601-8. PubMed ID: 26936920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
    Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
    JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: An opportunity to achieve HBsAg loss in children with mother-to-child transmitted hepatitis B.
    Yao N; Wang J; Wu Y; Zhu Y; Feng Y; Fu S; Liu J; Yang Y; Zhao Y; Shi L; Yang N; Chen T
    J Viral Hepat; 2022 Sep; 29(9):748-755. PubMed ID: 35722733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.